Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932254 | 0.86 | NPC1 (0.46) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL13554388 | 0.86 | TP53 (0.49) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL13917915 | 0.83 | NPC1 (0.42) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL13917924 | 0.81 | TP53 (0.51) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL28364396 | 0.80 | NPC1 (0.41) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL28364398 | 0.80 | NPC1 (0.41) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL13554387 | 0.80 | CTDSP1 (0.43) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL16871074 | 0.77 | NPC1 (0.41) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL28368521 | 0.77 | NPC1 (0.41) | NPC1RAB9ANCOA1NCOA3KMT2A | |
| SCHEMBL17469558 | 0.75 | NPC1 (0.43) | NPC1RAB9ANCOA1NCOA3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160025713-A1 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | LIFE TECHNOLOGIES CORP (US) | 2016-01-28 | — | — | US | disclosed |
| US-9164099-B2 | Site-specific labeling of affinity tags in fusion proteins | Life Technologies Corporation (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140038856-A1 | Site-specific labeling of affinity tags in fusion proteins | Life Technologies Corporation (US) | 2014-02-06 | — | — | US | disclosed |
| US-20120270757-A1 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | Life Technologies Corporation (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160025713-A1 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | APBA1, F13A1, F13B | NPC1 3663/4885RAB9A 2987/4885NCOA1 3107/4885 |
| US-20120270757-A1 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | APBA1, NAPA, F13B | NPC1 3592/4885RAB9A 3430/4885NCOA1 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.